Home Drug IndexClinical Monograph

Rivaroxaban Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Anticoagulant

Subclass

Direct Oral Anticoagulant (DOAC) — Factor Xa inhibitor

Speciality

Haematology

Schedule (India)

Schedule H

Routes

Oral

Formulations

Tablets: 2.5 mg, 10 mg, 15 mg, 20 mg

Note: Oral suspension/granules NOT AVAILABLE in India

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation (NVAF)

Adults with CrCl ≥50 mL/min:

Parameter	Recommendation
Starting dose	20 mg once daily with food (evening meal preferred)
Titration	Not applicable
Usual maintenance dose	20 mg once daily
Maximum dose	20 mg/day

Adults with CrCl 15–49 mL/min:

Parameter	Recommendation
Starting dose	15 mg once daily with food
Titration	Not applicable
Usual maintenance dose	15 mg once daily
Maximum dose	15 mg/day

Clinical Notes:

Avoid if CrCl <15 mL/min
Must be taken with food to ensure adequate bioavailability (15 mg and 20 mg doses)
Contraindicated in valvular AF (mechanical prosthetic valves, moderate-to-severe mitral stenosis)

2. Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Adults — Acute Treatment Phase (Days 1–21):

Parameter	Recommendation
Starting dose	15 mg twice daily with food
Titration	Not applicable during loading phase
Duration	21 days
Maximum dose	30 mg/day (during loading phase)

Adults — Maintenance Phase (Day 22 onwards):

Parameter	Recommendation
Starting dose	20 mg once daily with food (from Day 22)
Titration	Not applicable
Usual maintenance dose	20 mg once daily
Maximum dose	20 mg/day

Clinical Notes:

Minimum treatment duration: 3 months
Provoked VTE (reversible risk factor): 3 months usually sufficient
Unprovoked or recurrent VTE: consider extended therapy beyond 3 months
Assess bleeding risk periodically during long-term therapy

3. Prevention of Recurrent DVT and PE (Extended Secondary Prevention)

Adults — After Completion of Initial Treatment:

Parameter	Recommendation
Starting dose	10 mg once daily (with or without food)
Titration	Not applicable
Usual maintenance dose	10 mg once daily
Maximum dose	20 mg once daily (may be used if high recurrence risk)

Clinical Notes:

Initiate after at least 6 months of standard anticoagulation
20 mg dose may be preferred if VTE recurred during anticoagulation or very high risk
Periodically reassess need for continued therapy versus bleeding risk

4. Prophylaxis of VTE after Elective Hip or Knee Replacement Surgery

Adults:

Parameter	Recommendation
Starting dose	10 mg once daily
Timing of first dose	6–10 hours post-surgery, after haemostasis established
Titration	Not applicable
Usual maintenance dose	10 mg once daily
Maximum dose	10 mg/day

Duration:

Knee replacement: 14 days
Hip replacement: 35 days

Clinical Notes:

May be taken with or without food (10 mg dose)
Delay initiation if surgical haemostasis concerns
Avoid if neuraxial catheter in situ (remove catheter before starting; see Cautions)

5. Secondary Prevention of Atherothrombotic Events in Chronic Coronary Artery Disease (CAD) or Peripheral Arterial Disease (PAD)

Adults — In Combination with Aspirin:

Parameter	Recommendation
Starting dose	Rivaroxaban 2.5 mg twice daily + Aspirin 75–100 mg once daily
Titration	Not applicable
Usual maintenance dose	Rivaroxaban 2.5 mg twice daily + Aspirin 75–100 mg once daily
Maximum dose	5 mg/day rivaroxaban (2.5 mg twice daily)

Clinical Notes:

Indicated for stable atherosclerotic vascular disease
Contraindicated in patients with prior stroke or TIA — increased intracranial bleeding risk
Continue long-term for secondary prevention
May be taken with or without food (2.5 mg dose)

Secondary Indications – Adults Only (Off-label)

Indication	Dose	Duration	Supervision	Evidence Basis
Left Ventricular Thrombus — OFF-LABEL	20 mg once daily with food (15 mg if CrCl 15–49)	Minimum 3 months; reassess with imaging	Specialist only (Cardiology)	Indian cardiology practice; observational studies suggest comparable efficacy to warfarin
Heparin-Induced Thrombocytopenia (HIT) — OFF-LABEL	15 mg BD for 21 days, then 20 mg OD	Until platelet recovery and clinical stability	Specialist only (Haematology)	Limited evidence; emerging practice when argatroban/fondaparinux unavailable
Antiphospholipid Syndrome (APS) — Triple-Positive — OFF-LABEL	NOT RECOMMENDED — Warfarin preferred	—	—	TRAPS trial showed inferior outcomes with rivaroxaban; avoid in high-risk APS

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications

Regulatory Status: NOT approved for routine paediatric use in India. Paediatric oral suspension formulation NOT AVAILABLE in India.

Age Restriction: Not recommended below 18 years except under specialist haematology/cardiology supervision.

Secondary Indications – Paediatric (Off-label)

Treatment of Acute VTE in Children — OFF-LABEL

Use only when LMWH or warfarin unsuitable and under specialist supervision

Minimum Age/Weight: ≥6 months of age, ≥2.6 kg body weight

Body Weight	Approximate Daily Dose	Administration
2.6–<12 kg	Weight-band based — requires specialist calculation	Crushed tablets in water/apple puree (not ideal; suspension not available)
12–<30 kg	10–15 mg/day in 1–2 divided doses	With food
≥30 kg	15–20 mg once daily	With food

Clinical Notes:

Dosing extrapolated from international paediatric trials (EINSTEIN-Jr)
Lack of appropriate paediatric formulation in India limits practical use
LMWH remains preferred anticoagulant in paediatric VTE in India
Requires close specialist supervision (paediatric haematology/cardiology)

Safety Monitoring:

CBC, renal function, liver function at baseline and periodically
Clinical monitoring for bleeding
Anti-Xa levels generally not required but may be considered in complex cases

Renal Adjustments

Rivaroxaban is approximately 33% renally excreted — dose adjustment required in renal impairment:

Indication	CrCl ≥50 mL/min	CrCl 30–49 mL/min	CrCl 15–29 mL/min	CrCl <15 mL/min
NVAF (stroke prevention)	20 mg OD	15 mg OD	15 mg OD (use with caution)	Avoid
VTE treatment (acute)	15 mg BD → 20 mg OD	15 mg BD → 20 mg OD	Use with caution; limited data	Avoid
VTE prevention (orthopaedic)	10 mg OD	10 mg OD	10 mg OD (use with caution)	Avoid
Extended VTE prevention	10 mg OD	10 mg OD	Use with caution	Avoid
CAD/PAD + Aspirin	2.5 mg BD	2.5 mg BD	Use with caution	Avoid

Dialysis:

Haemodialysis: Not recommended — rivaroxaban is highly protein-bound and not effectively dialysed
Peritoneal dialysis: Avoid — insufficient data

Monitoring: Reassess renal function every 6 months in stable patients; more frequently if acute illness, dehydration, or nephrotoxic drugs used.

Hepatic adjustment

Contraindications

Active clinically significant bleeding (including GI, intracranial, or any site)
Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
Severe renal impairment (CrCl <15 mL/min)
Known hypersensitivity to rivaroxaban or excipients
Pregnancy (particularly second and third trimesters)
Lesions at high risk of clinically significant bleeding (e.g., active peptic ulcer, recent brain/spinal surgery, intracranial neoplasm)
Concomitant treatment with any other anticoagulant (except during transition periods)
Concomitant use with strong CYP3A4 and P-glycoprotein inhibitors (e.g., ketoconazole, itraconazole, ritonavir, lopinavir)
Mechanical prosthetic heart valves
Moderate-to-severe mitral stenosis of rheumatic origin

Cautions

Moderate renal impairment (CrCl 15–49 mL/min) — dose reduction may be needed; monitor closely
Elderly patients (≥75 years) — increased bleeding risk
Low body weight (<50 kg) — potential for increased drug exposure
Concomitant use of antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor) — additive bleeding risk
Chronic NSAID use — increased GI bleeding risk
Recent major surgery or trauma
History of GI bleeding or peptic ulcer disease
Uncontrolled severe hypertension
Bronchiectasis or history of pulmonary bleeding
Neuraxial anaesthesia or spinal puncture — risk of epidural/spinal haematoma
- Delay rivaroxaban for at least 18 hours after catheter removal
- Remove catheter at least 18 hours after last rivaroxaban dose
Moderate hepatic impairment (Child-Pugh B) — increased exposure
Patients with antiphospholipid syndrome (especially triple-positive) — warfarin preferred

Pregnancy

Parameter	Details
Risk category	Contraindicated — crosses placenta; potential for fetal bleeding, teratogenicity (animal data)
Preferred alternatives	Low Molecular Weight Heparin (LMWH) — enoxaparin is anticoagulant of choice in pregnancy in India
When may be used	Only in exceptional circumstances if LMWH absolutely contraindicated and no alternative exists; requires specialist decision
Monitoring	If inadvertent exposure: fetal ultrasound for anomalies, monitor for bleeding; plan delivery with haematology input

Lactation

Parameter	Details
Compatibility	Not recommended during breastfeeding
Drug levels in milk	Excreted in breast milk; infant exposure uncertain
Preferred alternatives	LMWH (enoxaparin) — not excreted in breast milk; warfarin — compatible with breastfeeding
Infant monitoring	If exposure occurs: monitor for bleeding signs, bruising, feeding difficulties

Elderly

Parameter	Recommendation
Starting dose	Same as younger adults, but assess renal function before prescribing
Titration	Not applicable — fixed dosing regimen
Special risks	Increased bleeding risk (particularly GI and intracranial); higher prevalence of renal impairment; falls risk; polypharmacy with interacting drugs
Monitoring	Renal function at baseline and every 6 months; more frequently if acute illness; regular clinical assessment for bleeding

Major drug interactions

Drug/Class	Mechanism/Effect	Recommendation
Strong CYP3A4 + P-gp inhibitors (ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, lopinavir)	Marked increase in rivaroxaban exposure → high bleeding risk	Contraindicated — avoid concomitant use
Strong CYP3A4 inducers (rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's Wort)	Significant reduction in rivaroxaban levels → loss of efficacy	Avoid — therapeutic failure likely
Other anticoagulants (warfarin, LMWH, UFH, fondaparinux, other DOACs)	Additive anticoagulant effect → major bleeding risk	Avoid — exception: brief overlap during transition (specialist supervision)
Thrombolytics (alteplase, tenecteplase, streptokinase)	Markedly increased bleeding risk	Avoid concomitant use; hold rivaroxaban during thrombolysis
Dual antiplatelet therapy (DAPT — aspirin + P2Y12 inhibitor)	Significantly increased bleeding risk	Use with extreme caution; triple therapy duration should be minimised; specialist decision

Moderate drug interactions

Drug/Class	Effect	Recommendation
Single antiplatelet (aspirin, clopidogrel)	Increased bleeding risk	Use only when indicated (CAD/PAD); monitor for bleeding
NSAIDs (diclofenac, ibuprofen, naproxen)	Increased GI bleeding risk	Avoid chronic use; if short-term use required, consider gastroprotection
Moderate CYP3A4 inhibitors (erythromycin, clarithromycin, fluconazole, diltiazem, verapamil)	Modest increase in rivaroxaban levels	Use with caution; monitor for bleeding
Dronedarone	Increases rivaroxaban exposure	Avoid if possible; if used, monitor closely
Amiodarone	Mild increase in rivaroxaban levels	Generally acceptable; monitor for bleeding
SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine)	Increased bleeding tendency (platelet effect)	Monitor for bleeding; counsel patient
Proton pump inhibitors	No significant interaction	Can be used together; useful for gastroprotection

Common Adverse effects

Bleeding — minor (epistaxis, gingival bleeding, bruising, menorrhagia)
Anaemia (may be occult GI blood loss)
Nausea, dyspepsia
Diarrhoea or constipation
Dizziness
Headache
Peripheral oedema
Mild transaminase elevation
Fatigue

Serious Adverse effects

Adverse Effect	Clinical Action
Major bleeding (GI haemorrhage, intracranial haemorrhage, retroperitoneal bleeding)	Immediate discontinuation; supportive care; consider reversal agent (andexanet alfa if available) or prothrombin complex concentrate; hospitalisation
Spinal/Epidural haematoma (with neuraxial procedures)	Emergency — can cause permanent paralysis; urgent neurosurgical consultation
Severe hypersensitivity/Anaphylaxis	Discontinue immediately; emergency management
Hepatotoxicity (rare)	Discontinue if significant transaminase elevation (>3× ULN with symptoms)
Thrombocytopenia (rare)	Monitor; may need to discontinue
Compartment syndrome (in setting of bleeding)	Surgical emergency

Reversal in Major Bleeding:

Andexanet alfa — specific reversal agent (limited availability in India)
Prothrombin Complex Concentrate (PCC) — 4-factor PCC 25–50 units/kg
Tranexamic acid — adjunctive
Activated charcoal — if ingestion within 2 hours
No role for FFP, vitamin K, or protamine

Monitoring requirements

Baseline:

Complete blood count (haemoglobin, platelet count)
Renal function (serum creatinine, calculated CrCl)
Liver function tests (transaminases, bilirubin)
Coagulation screen (PT/INR) — for baseline documentation only, not for monitoring
Bleeding risk assessment (HAS-BLED score for AF patients)

After Initiation / Dose Change:

Clinical assessment for bleeding at 1 month
Renal function at 1–3 months (especially in elderly, CKD, acute illness)
Haemoglobin if bleeding suspected

Long-term Monitoring:

Renal function: Every 6–12 months in stable patients; more frequently if CrCl <60 or at-risk (elderly, diabetes, heart failure, dehydration)
Haemoglobin and haematocrit: Annually or if bleeding symptoms
Liver function: Annually or if symptoms suggestive of hepatotoxicity
Clinical bleeding assessment at every visit
Reassess indication and bleeding risk annually

Note: Routine coagulation monitoring (PT/INR, aPTT) not required and not reliable for assessing rivaroxaban effect. Anti-Xa chromogenic assay (rivaroxaban-calibrated) may be used in special situations (overdose, emergency surgery, extremes of body weight).

Brands in India

Originator:

Xarelto (Bayer/Zydus)

Generic/Licensed Brands:

Rivasmart (Cipla)
Xaban (Dr. Reddy's)
Rivaxo (Sun Pharma)
Rivaxa (Torrent)
Rivonex (Mankind)
Xeralto (Macleods)
Rixova (Intas)
Rivaz (Alkem)

Fixed-Dose Combinations:

Rivaroxaban 2.5 mg + Aspirin 75 mg/100 mg — available from select manufacturers for CAD/PAD indication

Price range (INR)

Formulation	Approximate Price per Tablet
Tablet 2.5 mg	₹12–₹25
Tablet 10 mg	₹25–₹50
Tablet 15 mg	₹40–₹70
Tablet 20 mg	₹55–₹95

Not currently under NPPA price control
Not included in NLEM 2022
Significant price variation between originator and generic brands
Generic options substantially more affordable

Clinical pearls

Food is essential for higher doses — 15 mg and 20 mg doses must be taken with food to ensure adequate bioavailability (~66% fasting vs ~100% with food); 2.5 mg and 10 mg can be taken with or without food
Not for valvular AF — rivaroxaban is contraindicated in mechanical prosthetic valves and moderate-to-severe rheumatic mitral stenosis; use warfarin for these patients
Renal function determines dose in AF — always calculate CrCl (Cockcroft-Gault); if CrCl 15–49 mL/min, use 15 mg OD; avoid if <15 mL/min
No bridging required — unlike warfarin, rivaroxaban has rapid onset (2–4 hours) and offset; avoid overlapping with LMWH except in specific transition scenarios
Beware triple therapy — combination with DAPT (aspirin + P2Y12 inhibitor) markedly increases bleeding; minimise duration and consider 15 mg OD or 2.5 mg BD rivaroxaban in this setting (specialist decision)
Specific reversal agent availability is limited — andexanet alfa not widely available in India; PCC is the practical option for major bleeding
Prior stroke/TIA contraindicates vascular dose — do NOT use rivaroxaban 2.5 mg + aspirin combination in patients with prior stroke or TIA (intracranial bleeding risk)

Version

RxIndia v1.0 — 05 Jun 2025

Reference

- CDSCO approved product inserts
- Indian Pharmacopoeia
- API Textbook of Medicine
- AIIMS Anticoagulation Protocols
- Cardiological Society of India — AF and VTE management recommendations
- Bayer India Xarelto Prescribing Information
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (supportive)
- EINSTEIN-DVT, EINSTEIN-PE, ROCKET-AF, COMPASS trials (for indication context)
- EINSTEIN-Jr trial (for paediatric off-label context)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...